Literature DB >> 27797438

Putting T cells to work-outsourcing neoantigen detection in head and neck cancers?

R Xiao1,2,3, C Van Waes1, N C Schmitt1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27797438      PMCID： PMC5411338          DOI： 10.1111/odi.12604

Source DB:  PubMed          Journal:  Oral Dis        ISSN： 1354-523X            Impact factor:   3.511


× No keyword cloud information.
  9 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Authors:  Sanja Stevanović; Lindsey M Draper; Michelle M Langhan; Tracy E Campbell; Mei Li Kwong; John R Wunderlich; Mark E Dudley; James C Yang; Richard M Sherry; Udai S Kammula; Nicholas P Restifo; Steven A Rosenberg; Christian S Hinrichs
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

Review 3.  Immunology and Immunotherapy of Head and Neck Cancer.

Authors:  Robert L Ferris
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 4.  Adoptive cell transfer as personalized immunotherapy for human cancer.

Authors:  Steven A Rosenberg; Nicholas P Restifo
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

5.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.

Authors:  Erlend Strønen; Mireille Toebes; Sander Kelderman; Marit M van Buuren; Weiwen Yang; Nienke van Rooij; Marco Donia; Maxi-Lu Böschen; Fridtjof Lund-Johansen; Johanna Olweus; Ton N Schumacher
Journal:  Science       Date:  2016-05-19       Impact factor: 47.728

6.  Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.

Authors:  Tanguy Y Seiwert; Zhixiang Zuo; Michaela K Keck; Arun Khattri; Chandra S Pedamallu; Thomas Stricker; Christopher Brown; Trevor J Pugh; Petar Stojanov; Juok Cho; Michael S Lawrence; Gad Getz; Johannes Brägelmann; Rebecca DeBoer; Ralph R Weichselbaum; Alexander Langerman; Louis Portugal; Elizabeth Blair; Kerstin Stenson; Mark W Lingen; Ezra E W Cohen; Everett E Vokes; Kevin P White; Peter S Hammerman
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

Review 7.  Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.

Authors:  Clint T Allen; Paul E Clavijo; Carter Van Waes; Zhong Chen
Journal:  Cancers (Basel)       Date:  2015-12-09       Impact factor: 6.639

8.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

9.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Authors:  Laura Q M Chow; Robert Haddad; Shilpa Gupta; Amit Mahipal; Ranee Mehra; Makoto Tahara; Raanan Berger; Joseph Paul Eder; Barbara Burtness; Se-Hoon Lee; Bhumsuk Keam; Hyunseok Kang; Kei Muro; Jared Weiss; Ravit Geva; Chia-Chi Lin; Hyun Cheol Chung; Amy Meister; Marisa Dolled-Filhart; Kumudu Pathiraja; Jonathan D Cheng; Tanguy Y Seiwert
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.